PRRT2 and ovarian carcinoma: Interestingly, breast cancer cell (MDA-MB-231)-derived EVs carry miR-454 and disrupt the Wnt pathway by targeting proline-rich transmembrane protein 2 (PRRT2), thereby promoting CSC stemness and ovarian cancer cell growth in vivo.27